Theravance Biopharma
- Country
- Ownership
- -
- Employees
- 99
- Market Cap
- -
- Introduction
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded i...
Study of GSK961081 in Healthy Volunteer Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 46
- Registration Number
- NCT00887406
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 23
- Registration Number
- NCT00687700
- Locations
- π¬π§
GSK Investigational Site, Harrow, Middlesex, United Kingdom
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 45
- Registration Number
- NCT00674817
- Locations
- π¬π§
GSK Investigational Site, Manchester, United Kingdom
Succinate Salt Version of GSK961081 for Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 18
- Registration Number
- NCT00550225
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 203
- Registration Number
- NCT00442832
- Locations
- πΊπΈ
Allan Churukian, National City, California, United States
Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Theravance Biopharma
- Target Recruit Count
- 360
- Registration Number
- NCT00391820
- Locations
- πΊπΈ
Breco Research, Houston, Texas, United States
Β© Copyright 2024. All Rights Reserved by MedPath